Palmitoyl Pentapeptide-4 (Matrixyl)

A synthetic lipopeptide consisting of the pentapeptide sequence KTTKS conjugated to a palmitoyl (C16 fatty acid) chain. Developed by Sederma SAS and Procter & Gamble, it launched in 2000 under the trade name Matrixyl. KTTKS is the minimum effective fragment of procollagen type I C-terminal propeptide (residues 212-216), retaining approximately 80% of the parent molecule's extracellular matrix-stimulating activity.

It functions as a matrikine signal peptide that mimics collagen degradation products, stimulating fibroblasts to upregulate collagen I, collagen III, and fibronectin synthesis through TGF-beta signaling. The palmitoyl group enhances skin penetration by increasing lipophilicity. A landmark double-blind clinical study demonstrated statistically significant wrinkle reduction at concentrations as low as 3 ppm, with tolerability superior to retinol.

The landmark Robinson et al. (2005) double-blind, placebo-controlled, split-face study enrolled 93 women aged 35-55 and demonstrated that moisturizer containing 3 ppm Pal-KTTKS produced statistically significant wrinkle and fine line reduction vs. placebo over 12 weeks, measured by optical profilometry and expert grading. Comparative studies found 3 ppm Pal-KTTKS performed similarly to 700 ppm (0.07%) retinol for wrinkle improvement with superior tolerability.

Tsai et al. (2007) demonstrated that KTTKS promotes type I collagen expression through upregulation of TGF-beta signaling in tendon cells. Sederma's proprietary studies using 3D face acquisition over 28-56 days confirmed improvements in wrinkle depth, volume, and collagen content. The CIR Expert Panel completed a comprehensive safety assessment in September 2023, confirming safety for cosmetic use at current concentrations.